Biosciences
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.
Biotech IPO Market Sees Rare Upsurge with Triple Listing Success
Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering
Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases
Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.
Analysts Uncover Nuances in Avidity’s DMD Data, Highlighting Promising Results
Avidity Biosciences, DMD, Duchenne Muscular Dystrophy, RNA therapy, phase 1/2 data, clinical trials, biotech, pharmaceuticals
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure
Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback
Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.